Negative feedback regulation of bile acid metabolism: Impact on liver metabolism and diseases
John Y.L. Chiang – 29 June 2015
Prophylaxis of HCV reinfection and direct‐acting antiviral agents during liver transplantation
Marcello Tavio, Marco Vivarelli, Stefano Menzo, Andrea Gori, Paolo Antonio Grossi, Anna Marigliano – 29 June 2015
Reply
Phillip Hylemon, Masayuki Nagahashi, Kazuaki Takabe, Huiping Zhou – 29 June 2015
A metabolic chimera: Two defective genotypes make a normal phenotype
Sanjay Govil, Naresh P. Shanmugam, Mettu S. Reddy, Gomathy Narasimhan, Mohamed Rela – 29 June 2015
Reply
John B. Seal, Markus Selzner, George Loss – 29 June 2015
In a rapidly changing world, can we truly predict the impact of liver graft quality 15 years from now?
Russell H. Wiesner – 29 June 2015
Durability of small‐for‐size living donor allografts
Kin Pan Au, See Ching Chan, Kenneth Siu Ho Chok, Albert Chi Yan Chan, Tiffany Cho Lam Wong, William Wei Sharr, Chung Mau Lo – 29 June 2015 – Our aim was to study the long‐term outcomes of living donor liver transplantation using small‐for‐size (SFS) grafts. From July 2002 to July 2009, 233 patients received a right liver graft with a middle hepatic vein from a living donor in our center.
Bile acids and nonalcoholic fatty liver disease: An intriguing relationship
Lucia Carulli, Chiara Gabbi, Marco Bertolotti – 29 June 2015
4′‐modified nucleoside analogs: Potent inhibitors active against entecavir‐resistant hepatitis B virus
Yuki Takamatsu, Yasuhito Tanaka, Satoru Kohgo, Shuko Murakami, Kamalendra Singh, Debananda Das, David J. Venzon, Masayuki Amano, Nobuyo Higashi‐Kuwata, Manabu Aoki, Nicole S. Delino, Sanae Hayashi, Satoru Takahashi, Yoshikazu Sukenaga, Kazuhiro Haraguchi, Stefan G. Sarafianos, Kenji Maeda, Hiroaki Mitsuya – 29 June 2015 – Certain nucleoside/nucleotide reverse transcriptase (RT) inhibitors (NRTIs) are effective against human immunodeficiency virus type 1 (HIV‐1) and hepatitis B virus (HBV).
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection
Jean‐Michel Pawlotsky, Robert Flisiak, Shiv K. Sarin, Jens Rasenack, Teerha Piratvisuth, Wan‐Long Chuang, Cheng‐Yuan Peng, Graham R. Foster, Samir Shah, Heiner Wedemeyer, Christophe Hézode, Wei Zhang, Kelly A. Wong, Bin Li, Claudio Avila, Nikolai V. Naoumov, on behalf of the VITAL‐1 study team – 27 June 2015 – Alisporivir is a cyclophilin inhibitor with pan‐genotypic anti–hepatitis C virus (HCV) activity and a high barrier to viral resistance. The VITAL‐1 study assessed alisporivir as interferon (IFN)‐free therapy in treatment‐naïve patients infected with HCV genotype 2 or 3.